<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Clin Pract</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Clin. Pract</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1742-1241</journal-id><journal-id journal-id-type="publisher-id">IJCP</journal-id><journal-title-group><journal-title>International Journal of Clinical Practice</journal-title></journal-title-group><issn pub-type="ppub">1368-5031</issn><issn pub-type="epub">1742-1241</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28840637</article-id><article-id pub-id-type="pmc">5637912</article-id><article-id pub-id-type="doi">10.1111/ijcp.12987</article-id><article-id pub-id-type="publisher-id">IJCP12987</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Paper</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Papers</subject></subj-group></article-categories><title-group><article-title>Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension&#x02014;A randomized, open&#x02010;label, active&#x02010;controlled, superiority, parallel&#x02010;group clinical trial</article-title><alt-title alt-title-type="left-running-head">HWANG et&#x000a0;al.</alt-title></title-group><contrib-group><contrib id="ijcp12987-cr-0001" contrib-type="author"><name><surname>Hwang</surname><given-names>You&#x02010;Cheol</given-names></name><xref ref-type="aff" rid="ijcp12987-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ijcp12987-cr-0002" contrib-type="author"><name><surname>Yoon</surname><given-names>Kun&#x02010;Ho</given-names></name><xref ref-type="aff" rid="ijcp12987-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ijcp12987-cr-0003" contrib-type="author"><name><surname>Cha</surname><given-names>Bong&#x02010;Soo</given-names></name><xref ref-type="aff" rid="ijcp12987-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="ijcp12987-cr-0004" contrib-type="author"><name><surname>Lee</surname><given-names>Kwan&#x02010;Woo</given-names></name><xref ref-type="aff" rid="ijcp12987-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="ijcp12987-cr-0005" contrib-type="author"><name><surname>Jang</surname><given-names>Hak Chul</given-names></name><xref ref-type="aff" rid="ijcp12987-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="ijcp12987-cr-0006" contrib-type="author"><name><surname>Min</surname><given-names>Kyung Wan</given-names></name><xref ref-type="aff" rid="ijcp12987-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="ijcp12987-cr-0007" contrib-type="author"><name><surname>Chung</surname><given-names>Choon Hee</given-names></name><xref ref-type="aff" rid="ijcp12987-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="ijcp12987-cr-0008" contrib-type="author" corresp="yes"><name><surname>Lee</surname><given-names>Moon&#x02010;Kyu</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8728-7184</contrib-id><address><email>leemk@skku.edu</email></address><xref ref-type="aff" rid="ijcp12987-aff-0008">
<sup>8</sup>
</xref></contrib></contrib-group><aff id="ijcp12987-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Division of Endocrinology and Metabolism</named-content>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Kyung Hee University Hospital at Gangdong</institution>
<institution>Kyung Hee University School of Medicine</institution>
<named-content content-type="city">Seoul</named-content>
<country country="KP">Korea</country>
</aff><aff id="ijcp12987-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Endocrinology &#x00026; Metabolism</named-content>
<institution>Seoul St. Mary's Hospital</institution>
<institution>The Catholic University of Korea School of Medicine</institution>
<named-content content-type="city">Seoul</named-content>
<country country="KP">Korea</country>
</aff><aff id="ijcp12987-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Division of Endocrinology and Metabolism</named-content>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>Yonsei University College of Medicine</institution>
<named-content content-type="city">Seoul</named-content>
<country country="KP">Korea</country>
</aff><aff id="ijcp12987-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Endocrinology and Metabolism</named-content>
<institution>Ajou University School of Medicine</institution>
<named-content content-type="city">Gyunggi&#x02010;do</named-content>
<country country="KP">Korea</country>
</aff><aff id="ijcp12987-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>Seoul National University Bundang Hospital</institution>
<named-content content-type="city">Gyeonggi&#x02010;do</named-content>
<country country="KP">Korea</country>
</aff><aff id="ijcp12987-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>Eulji General Hospital</institution>
<institution>Eulji University School of Medicine</institution>
<named-content content-type="city">Seoul</named-content>
<country country="KP">Korea</country>
</aff><aff id="ijcp12987-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>Yonsei University Wonju College of Medicine</institution>
<named-content content-type="city">Wonju</named-content>
<country country="KP">Korea</country>
</aff><aff id="ijcp12987-aff-0008">
<label><sup>8</sup></label>
<named-content content-type="organisation-division">Division of Endocrinology and Metabolism</named-content>
<institution>Department of Medicine</institution>
<institution>Samsung Medical Center</institution>
<institution>Sungkyunkwan University School of Medicine</institution>
<named-content content-type="city">Seoul</named-content>
<country country="KP">Korea</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Moon&#x02010;Kyu Lee, Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.<break/>
Email: <email>leemk@skku.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2017</year></pub-date><volume>71</volume><issue>9</issue><issue-id pub-id-type="doi">10.1111/ijcp.2017.71.issue-9</issue-id><elocation-id>e12987</elocation-id><history><date date-type="received"><day>07</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>30</day><month>6</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>International Journal of Clinical Practice</italic> Published by John Wiley &#x00026; Sons Ltd</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:IJCP-71-na.pdf"/><abstract id="ijcp12987-abs-0001"><title>Summary</title><sec id="ijcp12987-sec-0001"><title>Background</title><p>It has been suggested that renoprotection with calcium channel blockers (CCBs) may differ. This study aimed to compare the anti&#x02010;proteinuric effect of different CCBs in patients with type 2 diabetes (T2D).</p></sec><sec id="ijcp12987-sec-0002"><title>Methods</title><p>A multicentre, randomized, open&#x02010;label, active&#x02010;controlled study was performed in seven centres in Korea. A total of 74 patients with T2D and microalbuminuria treated with renin&#x02010;angiotensin system (<styled-content style="fixed-case">RAS</styled-content>) blockers were randomized to a cilnidipine 10&#x000a0;mg treatment (n=38) or amlodipine 5&#x000a0;mg treatment (n=36).</p></sec><sec id="ijcp12987-sec-0003"><title>Results</title><p>Urine albumin to creatinine ratio (<styled-content style="fixed-case">ACR</styled-content>) reduction was similar between the two groups at 12&#x000a0;weeks (&#x02212;53.0&#x000b1;123.2&#x000a0;mg/g in cilnidipine group and &#x02212;35.7&#x000b1;83.6&#x000a0;mg/g in amlodipine group, <italic>P</italic>=.29) or 24&#x000a0;weeks (&#x02212;57.3&#x000b1;106.9&#x000a0;mg/g in cilnidipine group and &#x02212;20.0&#x000b1;110.4&#x000a0;mg/g in amlodipine group, <italic>P</italic>=.24). In a subgroup analysis, cilnidipine treatment showed a larger <styled-content style="fixed-case">ACR</styled-content> reduction than amlodipine treatment at 12&#x000a0;weeks (&#x02212;84.7&#x000b1;106.8&#x000a0;mg/g in cilnidipine group and &#x02212;9.5&#x000b1;79.2&#x000a0;mg/g in amlodipine group, <italic>P</italic>=.01) and 24&#x000a0;weeks (&#x02212;84.0&#x000b1;111.7&#x000a0;mg/g in cilnidipine group and 14.6&#x000b1;119.4&#x000a0;mg/g in amlodipine group, <italic>P</italic>=.008), particularly in patients with a longer duration of diabetes more than 10&#x000a0;years.</p></sec><sec id="ijcp12987-sec-0004"><title>Conclusions</title><p>Cilnidipine did not show any additional anti&#x02010;albuminuric effect compared with amlodipine in patients with T2D and microalbuminuria treated with an <styled-content style="fixed-case">RAS</styled-content> blocker. However, the anti&#x02010;albuminuric effect of cilnidipine might differ according to the duration of diabetes.</p></sec></abstract><funding-group><award-group><funding-source>Boryung Pharmaceutical Co, Ltd</funding-source></award-group></funding-group><counts><fig-count count="0"/><table-count count="4"/><page-count count="8"/><word-count count="6228"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>ijcp12987</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.1 mode:remove_FC converted:12.10.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ijcp12987-cit-1001">
<string-name>
<surname>Hwang</surname>
<given-names>Y&#x02010;C</given-names>
</string-name>, <string-name>
<surname>Yoon</surname>
<given-names>K&#x02010;H</given-names>
</string-name>, <string-name>
<surname>Cha</surname>
<given-names>B&#x02010;S</given-names>
</string-name>, et&#x000a0;al. <article-title>Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension&#x02014;A randomized, open&#x02010;label, active&#x02010;controlled, superiority, parallel&#x02010;group clinical trial</article-title>. <source>Int J Clin Pract</source>. <year>2017</year>;<volume>71</volume>:<elocation-id>e12987</elocation-id>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/ijcp.12987">https://doi.org/10.1111/ijcp.12987</ext-link>
</mixed-citation>
</p></notes></front><body><p>
<boxed-text position="anchor" content-type="box" id="ijcp12987-blkfxd-0001" orientation="portrait"><sec id="ijcp12987-sec-0006"><title>What's known</title><p>
<list list-type="bullet" id="ijcp12987-list-0001"><list-item><p>Renin&#x02010;angiotensin system blockers are the first&#x02010;line drug to control blood pressure in patients with diabetes.</p></list-item><list-item><p>Renoprotection with calcium channel blockers may differ according to the types of calcium channel.</p></list-item></list>
</p></sec><sec id="ijcp12987-sec-0007"><title>What's new</title><p>
<list list-type="bullet" id="ijcp12987-list-0002"><list-item><p>Anti&#x02010;albuminuric effect of cilnidipine is similar to that of amlodipine.</p></list-item><list-item><p>Anti&#x02010;albuminuric effect of cilnidipine differs according to duration of diabetes.</p></list-item><list-item><p>Anti&#x02010;albuminuric effect of cilnidipine is superior to that of amlodipine in patients with long duration of diabetes.</p></list-item></list>
</p></sec></boxed-text>
</p><sec id="ijcp12987-sec-0008"><label>1</label><title>INTRODUCTION</title><p>Microalbuminuria is an early sign of diabetic nephropathy<xref rid="ijcp12987-bib-0001" ref-type="ref">1</xref> and is associated with incident cardiovascular events.<xref rid="ijcp12987-bib-0002" ref-type="ref">2</xref>, <xref rid="ijcp12987-bib-0003" ref-type="ref">3</xref> It has been well known that tight blood pressure control with antihypertensive medications targeting the renin&#x02010;angiotensin system (RAS) can delay the deterioration of renal function and protect against cardiovascular events in patients with type 2&#x000a0;diabetes (T2D) and microalbuminuria.<xref rid="ijcp12987-bib-0004" ref-type="ref">4</xref> However, previous study showed that approximately three to four antihypertensive drugs are necessary to control blood pressure in patients with diabetes.<xref rid="ijcp12987-bib-0005" ref-type="ref">5</xref> Therefore, although RAS blockers are the first&#x02010;line option for controlling blood pressure in patients with diabetes, the majority of patients need another class of antihypertensive drugs in addition to RAS blocker. In addition, it was reported that combination of drugs with different mechanism of action reduces blood pressure more effectively with fewer adverse effects.<xref rid="ijcp12987-bib-0006" ref-type="ref">6</xref> Therefore, combination treatment of two different classes of antihypertensive medications showed a larger blood pressure reduction compared with doubling the dose of a single drug.<xref rid="ijcp12987-bib-0007" ref-type="ref">7</xref>
</p><p>For optimal blood pressure control, different classes of antihypertensive drugs can be added to angiotensin receptor blockers (ARBs) or angiotensin&#x02010;converting enzyme (ACE) inhibitors in patients with T2D. Among them, RAS blocker in combination with a calcium channel blocker (CCB) was reported to be better for reducing cardiovascular events than were diuretics.<xref rid="ijcp12987-bib-0008" ref-type="ref">8</xref> In addition, different voltage&#x02010;gated calcium channel subtypes, including L&#x02010;, T&#x02010;, N&#x02010; and P&#x02010;/Q&#x02010;types, have been suggested to be present within the renal vascular bed and tubules.<xref rid="ijcp12987-bib-0009" ref-type="ref">9</xref> In clinical practice, although L&#x02010;type CCBs are the most frequently prescribed CCBs, they mainly dilate afferent arterioles and possibly increase intraglomerular pressure. Therefore, L&#x02010;type CCBs may not be appropriate for patients with renal impairment.<xref rid="ijcp12987-bib-0009" ref-type="ref">9</xref> In contrast, N&#x02010;type calcium channels are present at peripheral sympathetic nerve endings, which innervate both afferent and efferent arterioles. Therefore, inhibiting N&#x02010;type calcium channels reduces intraglomerular pressure by dilating both afferent and efferent arterioles.<xref rid="ijcp12987-bib-0010" ref-type="ref">10</xref> Cilnidipine is a dual L&#x02010;/N&#x02010;type CCB and a previous study demonstrated that cilnidipine treatment significantly reduces urinary protein excretion compared with amlodipine treatment in patients with chronic kidney disease and hypertension receiving an RAS blocker.<xref rid="ijcp12987-bib-0011" ref-type="ref">11</xref>
</p><p>Therefore, this study aimed to compare the anti&#x02010;albuminuric effect of the L&#x02010;/N&#x02010;type CCB cilnidipine with the L&#x02010;type CCB amlodipine in patients with T2D who were treated with ARB or ACE inhibitor. In addition, we tried to determine whether cilnidipine has more favourable effects on glucose tolerance, lipid parameters and endothelial function compared with amlodipine.</p></sec><sec id="ijcp12987-sec-0009"><label>2</label><title>MATERIALS AND METHODS</title><sec id="ijcp12987-sec-0010"><label>2.1</label><title>Study subjects</title><p>Patients with T2D (age &#x02265;18&#x000a0;years) with an HbA1c level &#x02264;8.0% who had not used insulin for at least 12&#x000a0;weeks before screening were eligible to participate. Study participants had hypertension with microalbuminuria and were being treated with an ARB or ACE inhibitor for at least 12&#x000a0;weeks and had systolic and diastolic blood pressure controlled in the range of 100 to 140&#x000a0;mm Hg and &#x02264;90&#x000a0;mm Hg at entry, respectively. Study participants were eligible for the study if the urine albumin to creatinine ratio (ACR) ranged from 30 to 300&#x000a0;mg/g creatinine on two of three morning urine collections. Exclusion criteria were treatment with an antihypertensive drug other than RAS blocker within 2&#x000a0;weeks before randomization, serum creatinine level higher than normal, abnormal liver function test (AST/ALT &#x02265;&#x000a0;3 &#x000d7;&#x000a0;upper normal limit), severe hepatic dysfunction, severe aortic stenosis, use of drugs possibly affecting glucose metabolism (eg, glucocorticoid), and women who were pregnant or lactating. Lipid&#x02010;lowering drugs, anti&#x02010;platelet agents, anti&#x02010;thrombotics, and vasodilators were prohibited but could be used if the patients were prescribed the drugs before screening and did not change the dosage.</p><p>Considering 20% drop out rate, the required sample size was estimated as 74 that significant difference could be detected when the difference in the mean ACR change between both groups was 15&#x000a0;mg/g creatinine (statistical power: 80%, two&#x02010;sided level of significance: 5%) considering the previous report.<xref rid="ijcp12987-bib-0012" ref-type="ref">12</xref> Of the 157 screened patients with T2D, 83 were excluded, and 74 were enrolled in this study (intention&#x02010;to&#x02010;treat population). Among these 74 patients, 17 did not complete the study (withdrew informed consent, one patient; adverse effect, four patients; and violation of study protocol, 12 patients), and the remaining 57 patients were eligible for the per&#x02010;protocol analysis.</p><p>This study was conducted in accordance with the Declaration of Helsinki. Informed written consent was obtained from all participants, and the study was approved by the Internal Review Board of each participating centre.</p></sec><sec id="ijcp12987-sec-0011"><label>2.2</label><title>Study design</title><p>This was a 24&#x02010;week randomized, open&#x02010;label, active&#x02010;controlled, superiority, parallel&#x02010;group clinical trial conducted at seven centres in Korea. The study included a 2&#x02010; to 4&#x02010;week run&#x02010;in period. If the systolic and diastolic blood pressure was maintained at 100&#x02010;150&#x000a0;mm Hg and &#x0003c;90&#x000a0;mm Hg, respectively, during the run&#x02010;in period, the patient was eligible for the study and began a 24&#x02010;week active treatment period. Eligible patients were randomly assigned to cilnidipine treatment (10&#x000a0;mg daily) or amlodipine treatment (5&#x000a0;mg daily) in combination with an ARB or ACE inhibitor. If blood pressure was low after randomization and caused a safety concern, the RAS blocker dosage could be titrated according to the investigator's decision. Clinic visits were scheduled 4, 12 and 24&#x000a0;weeks after randomization. Adherence to medication was assessed at each visit by pill counting, and non&#x02010;adherent patients (&#x0003c;70%) were eliminated from the study.</p><p>The primary end&#x02010;point was change in urine ACR from the pretreatment period to 12 and 24&#x000a0;weeks. The secondary end&#x02010;points included metabolic parameters and endothelial function test at 12 and 24&#x000a0;weeks and change in blood pressure at 24&#x000a0;weeks.</p></sec><sec id="ijcp12987-sec-0012"><label>2.3</label><title>Clinical and laboratory examination</title><p>Comprehensive physical examination was performed at baseline, and personal medical history including smoking status, alcohol drinking, and physical activity were assessed by a questionnaire. Body mass index was calculated as the weight divided by the square of height (kg/m<sup>2</sup>). Waist circumference was measured at the midline between the iliac crest and the rib edge in a standing position. After resting at least 5&#x000a0;minutes, blood pressure was measured with an automatic sphygmomanometer in a seated position. Blood pressure was measured twice at 2&#x02010;min intervals, and the mean value of two stable measurements (difference of &#x0003c;5&#x000a0;mm&#x02009;Hg) was used.</p><p>All blood tests were determined after an overnight fast more than 8&#x000a0;hours. Using an autoanalyzer, plasma glucose was measured by the hexokinase method. Plasma insulin was measured by radioimmunoassay. To estimate insulin sensitivity and insulin secretory capacity, the homoeostasis model assessment of insulin resistance (HOMA&#x02010;IR) and HOMA&#x02010;B% was calculated, respectively, based on fasting serum insulin and FPG levels.<xref rid="ijcp12987-bib-0013" ref-type="ref">13</xref> The standard enzymatic method was used to measure total cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol. HbA1c level was measured by high&#x02010;performance liquid chromatography. The Cockcroft&#x02010;Gault formula was used to estimate glomerular filtration rate (GFR).<xref rid="ijcp12987-bib-0014" ref-type="ref">14</xref> Urinary albumin concentration (&#x003bc;g) was measured using a turbidimetric immunoassay. Urinary creatinine concentration (mg) was measured with a colorimetric method, and ACR (mg/g) was calculated by dividing the urinary albumin concentration by the urinary creatinine concentration.<xref rid="ijcp12987-bib-0015" ref-type="ref">15</xref> Serum total adiponectin, plasminogen activator inhibitor&#x02010;1 (PAI&#x02010;1), and 8&#x02010;isoprostane levels were measured with commercial enzyme linked&#x02010;immunosorbent assay (ELISA) kits. Serum cystatin C level was measured by the immuno&#x02010;nephelometry&#x000a0;method.</p><p>After 5&#x000a0;minutes rest in the supine position, brachial&#x02010;ankle pulse wave velocity (baPWV) and Ankle Brachial Index (ABI) were determined using an automatic device (VP&#x02010;2000; Colin, Komaki, Japan). Briefly, blood pressures were measured in the both arms and legs and simultaneously recorded pulse waves using an oscillometric cuff technique.</p></sec><sec id="ijcp12987-sec-0013"><label>2.4</label><title>Statistical analysis</title><p>Data are expressed as mean&#x000b1;SD for continuous variables and as proportion for categorical variables. To compare differences between groups, independent <italic>t</italic>&#x02010;test or Wilcoxon's rank&#x02010;sum test and &#x003c7;<sup>2</sup> test or Fisher's exact test were used for continuous variables and for categorical variables, respectively. Paired t&#x02010;test was used to compare differences within groups before and after treatment. All statistical analyses were performed using <sc>sas</sc> 9.3 (SAS Institute, Cary, NC). A <italic>P</italic> &#x0003c;.05 was considered significant.</p></sec></sec><sec id="ijcp12987-sec-0014"><label>3</label><title>RESULTS</title><p>Table&#x000a0;<xref rid="ijcp12987-tbl-0001" ref-type="table-wrap">1</xref> shows the baseline characteristics of study participants. The mean age was 61.0&#x000a0;years and 59.8&#x000a0;years in cilnidipine and amlodipine groups, respectively, and 68.9% of subjects were male. Blood pressure and glucose were well controlled in both groups, and no differences were noted between the two groups. In addition, renal function as estimated by GFR was slightly impaired (stage 2) and did not differ between groups (75.5&#x000b1;21.2&#x000a0;mL/min in the cilnidipine group and 78.0&#x000b1;23.6&#x000a0;mL/min in the amlodipine group, <italic>P</italic>=.78).</p><table-wrap id="ijcp12987-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of study subjects (intention&#x02010;to&#x02010;treat analysis)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="char" valign="top" rowspan="1" colspan="1">Cilnidipine (n=38)</th><th align="char" valign="top" rowspan="1" colspan="1">Amlodipine (n=36)</th><th align="char" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (y)</td><td align="char" char="(" rowspan="1" colspan="1">61.0 (8.5)</td><td align="char" char="(" rowspan="1" colspan="1">59.8 (10.4)</td><td align="char" char="." rowspan="1" colspan="1">.59</td></tr><tr><td align="left" rowspan="1" colspan="1">Male (%)</td><td align="char" char="(" rowspan="1" colspan="1">28 (73.7)</td><td align="char" char="(" rowspan="1" colspan="1">23 (63.9)</td><td align="char" char="." rowspan="1" colspan="1">.36</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoking (%)</td><td align="char" char="(" rowspan="1" colspan="1">5 (13.2)</td><td align="char" char="(" rowspan="1" colspan="1">10 (27.8)</td><td align="char" char="." rowspan="1" colspan="1">.29</td></tr><tr><td align="left" rowspan="1" colspan="1">Alcohol consumption (%)</td><td align="char" char="(" rowspan="1" colspan="1">17 (44.7)</td><td align="char" char="(" rowspan="1" colspan="1">13 (36.1)</td><td align="char" char="." rowspan="1" colspan="1">.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="char" char="(" rowspan="1" colspan="1">24.4 (2.7)</td><td align="char" char="(" rowspan="1" colspan="1">24.6 (2.8)</td><td align="char" char="." rowspan="1" colspan="1">.78</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference (cm)</td><td align="char" char="(" rowspan="1" colspan="1">85.6 (9.6)</td><td align="char" char="(" rowspan="1" colspan="1">87.1 (6.7)</td><td align="char" char="." rowspan="1" colspan="1">.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Hip circumference (cm)</td><td align="char" char="(" rowspan="1" colspan="1">95.8 (6.6)</td><td align="char" char="(" rowspan="1" colspan="1">97.2 (6.2)</td><td align="char" char="." rowspan="1" colspan="1">.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mm Hg)</td><td align="char" char="(" rowspan="1" colspan="1">125.3 (10.8)</td><td align="char" char="(" rowspan="1" colspan="1">125.6 (11.0)</td><td align="char" char="." rowspan="1" colspan="1">.89</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mm Hg)</td><td align="char" char="(" rowspan="1" colspan="1">74.0 (7.5)</td><td align="char" char="(" rowspan="1" colspan="1">76.2 (8.6)</td><td align="char" char="." rowspan="1" colspan="1">.25</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate (beat/min)</td><td align="char" char="(" rowspan="1" colspan="1">75.0 (7.4)</td><td align="char" char="(" rowspan="1" colspan="1">75.2 (9.4)</td><td align="char" char="." rowspan="1" colspan="1">.93</td></tr><tr><td align="left" rowspan="1" colspan="1">White blood cells (10<sup>9</sup>/L)</td><td align="char" char="(" rowspan="1" colspan="1">6.4 (1.6)</td><td align="char" char="(" rowspan="1" colspan="1">6.5 (1.8)</td><td align="char" char="." rowspan="1" colspan="1">.77</td></tr><tr><td align="left" rowspan="1" colspan="1">Haemoglobin (g/L)</td><td align="char" char="(" rowspan="1" colspan="1">139.2 (12.1)</td><td align="char" char="(" rowspan="1" colspan="1">140.3 (15.3)</td><td align="char" char="." rowspan="1" colspan="1">.71</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelets (10<sup>9</sup>/L)</td><td align="char" char="(" rowspan="1" colspan="1">234.8 (63.0)</td><td align="char" char="(" rowspan="1" colspan="1">231.7 (54.2)</td><td align="char" char="." rowspan="1" colspan="1">.91</td></tr><tr><td align="left" rowspan="1" colspan="1">Total bilirubin (&#x003bc;mol/L)</td><td align="char" char="(" rowspan="1" colspan="1">14.5 (6.5)</td><td align="char" char="(" rowspan="1" colspan="1">12.8 (5.3)</td><td align="char" char="." rowspan="1" colspan="1">.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein (g/L)</td><td align="char" char="(" rowspan="1" colspan="1">72.0 (3.7)</td><td align="char" char="(" rowspan="1" colspan="1">72.0 (4.4)</td><td align="char" char="." rowspan="1" colspan="1">.96</td></tr><tr><td align="left" rowspan="1" colspan="1">Albumin (g/L)</td><td align="char" char="(" rowspan="1" colspan="1">45.0 (2.7)</td><td align="char" char="(" rowspan="1" colspan="1">45.0 (3.0)</td><td align="char" char="." rowspan="1" colspan="1">.91</td></tr><tr><td align="left" rowspan="1" colspan="1">Aspartate aminotransferase (U/L)</td><td align="char" char="(" rowspan="1" colspan="1">26.1 (13.7)</td><td align="char" char="(" rowspan="1" colspan="1">21.5 (6.4)</td><td align="char" char="." rowspan="1" colspan="1">.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Alanine transaminase (U/L)</td><td align="char" char="(" rowspan="1" colspan="1">24.5 (13.5)</td><td align="char" char="(" rowspan="1" colspan="1">24.8 (15.7)</td><td align="char" char="." rowspan="1" colspan="1">.73</td></tr><tr><td align="left" rowspan="1" colspan="1">Alkaline phosphatase (U/L)</td><td align="char" char="(" rowspan="1" colspan="1">66.9 (19.0)</td><td align="char" char="(" rowspan="1" colspan="1">66.8 (20.0)</td><td align="char" char="." rowspan="1" colspan="1">.82</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood urea nitrogen (mmol/L)</td><td align="char" char="(" rowspan="1" colspan="1">5.74 (1.45)</td><td align="char" char="(" rowspan="1" colspan="1">5.98 (1.78)</td><td align="char" char="." rowspan="1" colspan="1">.72</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (&#x003bc;mol/L)</td><td align="char" char="(" rowspan="1" colspan="1">84.9 (15.0)</td><td align="char" char="(" rowspan="1" colspan="1">80.4 (14.1)</td><td align="char" char="." rowspan="1" colspan="1">.18</td></tr><tr><td align="left" rowspan="1" colspan="1">Estimated GFR (mL/min)</td><td align="char" char="(" rowspan="1" colspan="1">75.5 (21.2)</td><td align="char" char="(" rowspan="1" colspan="1">78.0 (23.6)</td><td align="char" char="." rowspan="1" colspan="1">.78</td></tr><tr><td align="left" rowspan="1" colspan="1">Na (mmol/L)</td><td align="char" char="(" rowspan="1" colspan="1">140.6 (2.1)</td><td align="char" char="(" rowspan="1" colspan="1">140.9 (2.1)</td><td align="char" char="." rowspan="1" colspan="1">.42</td></tr><tr><td align="left" rowspan="1" colspan="1">K (mmol/L)</td><td align="char" char="(" rowspan="1" colspan="1">4.6 (0.4)</td><td align="char" char="(" rowspan="1" colspan="1">4.6 (0.4)</td><td align="char" char="." rowspan="1" colspan="1">.76</td></tr><tr><td align="left" rowspan="1" colspan="1">Cl (mmol/L)</td><td align="char" char="(" rowspan="1" colspan="1">102.3 (2.8)</td><td align="char" char="(" rowspan="1" colspan="1">103.1 (2.9)</td><td align="char" char="." rowspan="1" colspan="1">.23</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting plasma glucose (mmol/L)</td><td align="char" char="(" rowspan="1" colspan="1">7.07 (1.18)</td><td align="char" char="(" rowspan="1" colspan="1">6.92 (1.32)</td><td align="char" char="." rowspan="1" colspan="1">.80</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c (%)</td><td align="char" char="(" rowspan="1" colspan="1">6.7 (0.6)</td><td align="char" char="(" rowspan="1" colspan="1">6.8 (0.6)</td><td align="char" char="." rowspan="1" colspan="1">.46</td></tr></tbody></table><table-wrap-foot><fn id="ijcp12987-note-0001"><p>Data are expressed as mean (SD) or proportion (%).</p></fn><fn id="ijcp12987-note-0002"><p>Independent <italic>t</italic>&#x02010;test or Wilcoxon's rank&#x02010;sum test were used.</p></fn><fn id="ijcp12987-note-0003"><p>GFR, glomerular filtration rate.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>At baseline, subjects in both groups had similar urinary albumin excretion (138.2&#x000b1;109.9&#x000a0;mg/g in the cilnidipine group and 97.1&#x000b1;66.3&#x000a0;mg/g in the amlodipine group, <italic>P</italic>=.11). After 12&#x000a0;weeks, subjects in the cilnidipine group showed a significant decrease in ACR from baseline both in the intention&#x02010;to&#x02010;treat (&#x02212;53.0&#x000b1;123.2&#x000a0;mg/g, <italic>P</italic>=.003) and per&#x02010;protocol analyses (&#x02212;59.6&#x000b1;135.1&#x000a0;mg/g, <italic>P</italic>=.007). In addition, the anti&#x02010;albuminuric effect of cilnidipine persisted for up to 24&#x000a0;weeks in the cilnidipine group (&#x02212;57.3&#x000b1;106.9&#x000a0;mg/g in intention&#x02010;to&#x02010;treat, <italic>P</italic>=.004 and &#x02212;65.5&#x000b1;112.3&#x000a0;mg/g in per&#x02010;protocol, <italic>P</italic>=.006). The amlodipine treatment could not decrease in ACR at 12 or 24&#x000a0;weeks. The decrease in ACR did not differ between groups at 12 and 24&#x000a0;weeks (Table&#x000a0;<xref rid="ijcp12987-tbl-0002" ref-type="table-wrap">2</xref>).</p><table-wrap id="ijcp12987-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Changes in urine albumin creatinine ratio</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Intention&#x02010;to&#x02010;treat analysis</th><th align="char" valign="top" rowspan="1" colspan="1">Cilnidipine (n=38)</th><th align="char" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
<xref ref-type="fn" rid="ijcp12987-note-0004">a</xref>
</th><th align="char" valign="top" rowspan="1" colspan="1">Amlodipine (n=36)</th><th align="char" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
<xref ref-type="fn" rid="ijcp12987-note-0004">a</xref>
</th><th align="char" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
<xref ref-type="fn" rid="ijcp12987-note-0005">b</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="char" rowspan="1" colspan="1">138.2 (109.9)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">97.1 (66.3)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference from baseline (12&#x000a0;wk)</td><td align="char" rowspan="1" colspan="1">&#x02212;53.0 (123.2)</td><td align="char" rowspan="1" colspan="1">.003</td><td align="char" rowspan="1" colspan="1">&#x02212;35.7 (83.6)</td><td align="char" rowspan="1" colspan="1">.07</td><td align="char" rowspan="1" colspan="1">.29</td></tr><tr style="border-bottom:solid 1px #000000"><td align="left" rowspan="1" colspan="1">Difference from baseline (24&#x000a0;wk)</td><td align="char" rowspan="1" colspan="1">&#x02212;57.3 (106.9)</td><td align="char" rowspan="1" colspan="1">.004</td><td align="char" rowspan="1" colspan="1">&#x02212;20.0 (110.4)</td><td align="char" rowspan="1" colspan="1">.31</td><td align="char" rowspan="1" colspan="1">.24</td></tr><tr style="border-bottom:solid 1px #000000"><td align="left" rowspan="1" colspan="1">
<bold>Per&#x02010;protocol analysis</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>Cilnidipine (n=27)</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold><italic>P</italic></bold>
<xref ref-type="fn" rid="ijcp12987-note-0004">a</xref>
</td><td align="char" rowspan="1" colspan="1">
<bold>Amlodipine (n=30)</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold><italic>P</italic></bold>
<xref ref-type="fn" rid="ijcp12987-note-0004">a</xref>
</td><td align="char" rowspan="1" colspan="1">
<bold><italic>P</italic></bold>
<xref ref-type="fn" rid="ijcp12987-note-0005">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="char" rowspan="1" colspan="1">141.0 (99.5)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">99.5 (68.0)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference from baseline (12&#x000a0;wk)</td><td align="char" rowspan="1" colspan="1">&#x02212;59.6 (135.1)</td><td align="char" rowspan="1" colspan="1">.007</td><td align="char" rowspan="1" colspan="1">&#x02212;39.1 (90.2)</td><td align="char" rowspan="1" colspan="1">.12</td><td align="char" rowspan="1" colspan="1">.22</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference from baseline (24&#x000a0;wk)</td><td align="char" rowspan="1" colspan="1">&#x02212;65.5 (112.3)</td><td align="char" rowspan="1" colspan="1">.006</td><td align="char" rowspan="1" colspan="1">&#x02212;25.2 (118.2)</td><td align="char" rowspan="1" colspan="1">.20</td><td align="char" rowspan="1" colspan="1">.33</td></tr></tbody></table><table-wrap-foot><fn id="ijcp12987-note-0004"><label>a</label><p>vs baseline within group.</p></fn><fn id="ijcp12987-note-0005"><label>b</label><p>Between groups.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>We next divided study participants according to duration of diabetes. ACR reduction was similar between the two groups in patients with diabetes duration shorter than 10&#x000a0;years. However, in patients with diabetes longer than 10&#x000a0;years, the cilnidipine group showed a greater decrease in ACR than did the amlodipine group at 12&#x000a0;weeks (&#x02212;84.7&#x000b1;106.8&#x000a0;mg/g in the cilnidipine group and &#x02212;9.5&#x000b1;79.2&#x000a0;mg/g in the amlodipine group, <italic>P</italic>=.010) and 24&#x000a0;weeks (&#x02212;84.0&#x000b1;111.7&#x000a0;mg/g in the cilnidipine group and 14.6&#x000b1;119.4&#x000a0;mg/g in the amlodipine group, <italic>P</italic>=.008) (Table&#x000a0;<xref rid="ijcp12987-tbl-0003" ref-type="table-wrap">3</xref>).</p><table-wrap id="ijcp12987-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Changes in urine albumin creatinine ratio by duration of diabetes</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Diabetes duration &#x0003c;10&#x000a0;y</th><th align="char" valign="top" rowspan="1" colspan="1">Cilnidipine (n=18)</th><th align="char" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
<xref ref-type="fn" rid="ijcp12987-note-0006">a</xref>
</th><th align="char" valign="top" rowspan="1" colspan="1">Amlodipine (n=18)</th><th align="char" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
<xref ref-type="fn" rid="ijcp12987-note-0006">a</xref>
</th><th align="char" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
<xref ref-type="fn" rid="ijcp12987-note-0007">b</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="char" char="." rowspan="1" colspan="1">127.1 (83.8)</td><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">99.2 (68.8)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">.30</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference from baseline (12&#x000a0;wk)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;17.7 (133.4)</td><td align="char" char="." rowspan="1" colspan="1">.53</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;61.9 (81.7)</td><td align="char" rowspan="1" colspan="1">.007</td><td align="char" rowspan="1" colspan="1">.21</td></tr><tr style="border-bottom:solid 1px #000000"><td align="left" rowspan="1" colspan="1">Difference from baseline (24&#x000a0;wk)</td><td align="char" char="." rowspan="1" colspan="1">27.8 (95.8)</td><td align="char" char="." rowspan="1" colspan="1">.71</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;54.5 (91.1)</td><td align="char" rowspan="1" colspan="1">.054</td><td align="char" rowspan="1" colspan="1">.35</td></tr><tr style="border-bottom:solid 1px #000000"><td align="left" rowspan="1" colspan="1">
<bold>Diabetes duration &#x02265;10&#x000a0;y</bold>
</td><td align="char" char="." rowspan="1" colspan="1">
<bold>Cilnidipine (n=20)</bold>
</td><td align="char" char="." rowspan="1" colspan="1">
<bold><italic>P</italic></bold>
<xref ref-type="fn" rid="ijcp12987-note-0006">a</xref>
</td><td align="char" char="." rowspan="1" colspan="1">
<bold>Amlodipine (n=18)</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold><italic>P</italic></bold>
<xref ref-type="fn" rid="ijcp12987-note-0006">a</xref>
</td><td align="char" rowspan="1" colspan="1">
<bold><italic>P</italic></bold>
<xref ref-type="fn" rid="ijcp12987-note-0007">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="char" char="." rowspan="1" colspan="1">148.1 (130.5)</td><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">94.9 (65.5)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">.19</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference from baseline (12&#x000a0;wk)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;84.7 (106.8)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.001</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;9.5 (79.2)</td><td align="char" rowspan="1" colspan="1">.78</td><td align="char" rowspan="1" colspan="1">.010</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference from baseline (24&#x000a0;wk)</td><td align="char" rowspan="1" colspan="1">&#x02212;84.0 (111.7)</td><td align="char" char="." rowspan="1" colspan="1">.003</td><td align="char" char="." rowspan="1" colspan="1">14.6 (119.4)</td><td align="char" rowspan="1" colspan="1">.54</td><td align="char" rowspan="1" colspan="1">.008</td></tr></tbody></table><table-wrap-foot><fn id="ijcp12987-note-0006"><label>a</label><p>vs baseline within group.</p></fn><fn id="ijcp12987-note-0007"><label>b</label><p>Between groups.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>In terms of metabolic parameters, fasting glucose and glycated haemoglobin level, lipid measurements, and insulin sensitivity and resistance measures determined by HOMA&#x02010;IR did not differ between the two groups at 12 or 24&#x000a0;weeks. In addition, adiponectin, high&#x02010;sensitivity C&#x02010;reactive protein (hsCRP), 8&#x02010;isoprostane, and cystatin C levels were similar between the two groups. The cilnidipine group showed a greater decrease in PAI&#x02010;1 level than did the amlodipine group at 12&#x000a0;weeks (&#x02212;2.8&#x000b1;10.1&#x000a0;ng/mL in the cilnidipine group and 2.2&#x000b1;16.1&#x000a0;ng/mL in the amlodipine group, <italic>P</italic>=.011). However, at 24&#x000a0;weeks, the amlodipine group had a greater decrease in diastolic blood pressure (2.0&#x000b1;7.4&#x000a0;mm Hg in the cilnidipine group and &#x02212;1.9&#x000b1;8.0&#x000a0;mm Hg in the amlodipine group, <italic>P</italic>=.035) and brachial artery pulse wave velocity (right: 55.0&#x000b1;193.5&#x000a0;cm/s in the cilnidipine group and &#x02212;40.6&#x000b1;213.1&#x000a0;cm/s in the amlodipine group, <italic>P</italic>=.05; left: 29.0&#x000b1;179.4&#x000a0;cm/s in the cilnidipine group and &#x02212;63.7&#x000b1;207.9&#x000a0;cm/s in the amlodipine group, <italic>P</italic>=.046) than did the cilnidipine group (Table&#x000a0;<xref rid="ijcp12987-tbl-0004" ref-type="table-wrap">4</xref>).</p><table-wrap id="ijcp12987-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Changes in cardiometabolic parameters (intention&#x02010;to&#x02010;treat analysis)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="char" valign="top" rowspan="1" colspan="1">Baseline</th><th align="char" valign="top" rowspan="1" colspan="1">Difference from baseline after 12&#x000a0;wk</th><th align="char" valign="top" rowspan="1" colspan="1">Difference from baseline after 24&#x000a0;wk</th><th align="char" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
<xref ref-type="fn" rid="ijcp12987-note-0008">a</xref>
</th><th align="char" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
<xref ref-type="fn" rid="ijcp12987-note-0009">b</xref>
</th><th align="char" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
<xref ref-type="fn" rid="ijcp12987-note-0010">c</xref>
</th><th align="char" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
<xref ref-type="fn" rid="ijcp12987-note-0011">d</xref>
</th></tr></thead><tbody><tr><td align="left" colspan="8" rowspan="1">Systolic blood pressure (mm Hg)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">125.3 (10.8)</td><td align="char" rowspan="1" colspan="1">1.5 (9.5)</td><td align="char" char="(" rowspan="1" colspan="1">2.3 (10.2)</td><td align="char" rowspan="1" colspan="1">.35</td><td align="char" char="." rowspan="1" colspan="1">.17</td><td align="char" rowspan="1" colspan="1">.06</td><td align="char" char="." rowspan="1" colspan="1">.09</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">125.7 (11.0)</td><td align="char" rowspan="1" colspan="1">&#x02212;4.4 (11.0)</td><td align="char" rowspan="1" colspan="1">&#x02212;2.9 (15.4)</td><td align="char" rowspan="1" colspan="1">.028</td><td align="char" char="." rowspan="1" colspan="1">.27</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">Diastolic blood pressure (mm Hg)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">74.0 (7.5)</td><td align="char" rowspan="1" colspan="1">0.7 (7.8)</td><td align="char" char="(" rowspan="1" colspan="1">2.0 (7.4)</td><td align="char" rowspan="1" colspan="1">.59</td><td align="char" char="." rowspan="1" colspan="1">.11</td><td align="char" rowspan="1" colspan="1">0.30</td><td align="char" char="." rowspan="1" colspan="1">.035</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">76.2 (8.6)</td><td align="char" rowspan="1" colspan="1">&#x02212;1.2 (7.4)</td><td align="char" rowspan="1" colspan="1">&#x02212;1.9 (8.0)</td><td align="char" rowspan="1" colspan="1">.36</td><td align="char" char="." rowspan="1" colspan="1">0.17</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">Heart rate (beat/min)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">75.0 (7.4)</td><td align="char" rowspan="1" colspan="1">&#x02212;2.8 (5.0)</td><td align="char" rowspan="1" colspan="1">&#x02212;1.5 (7.9)</td><td align="char" rowspan="1" colspan="1">.001</td><td align="char" char="." rowspan="1" colspan="1">0.24</td><td align="char" rowspan="1" colspan="1">0.43</td><td align="char" char="." rowspan="1" colspan="1">.63</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">75.2 (9.4)</td><td align="char" rowspan="1" colspan="1">&#x02212;1.6 (7.3)</td><td align="char" rowspan="1" colspan="1">&#x02212;2.0 (7.6)</td><td align="char" rowspan="1" colspan="1">.19</td><td align="char" char="." rowspan="1" colspan="1">0.032</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">Fasting plasma glucose (mmol/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">7.07 (1.18)</td><td align="char" rowspan="1" colspan="1">0.12 (1.29)</td><td align="char" char="(" rowspan="1" colspan="1">0.38 (0.98)</td><td align="char" rowspan="1" colspan="1">.58</td><td align="char" char="." rowspan="1" colspan="1">0.06</td><td align="char" rowspan="1" colspan="1">0.90</td><td align="char" char="." rowspan="1" colspan="1">.57</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">6.92 (1.32)</td><td align="char" rowspan="1" colspan="1">0.16 (1.45)</td><td align="char" char="(" rowspan="1" colspan="1">0.29 (1.17)</td><td align="char" rowspan="1" colspan="1">.53</td><td align="char" char="." rowspan="1" colspan="1">0.41</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">HbA1c (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">6.7 (0.6)</td><td align="char" rowspan="1" colspan="1">0.2 (0.5)</td><td align="char" char="(" rowspan="1" colspan="1">0.2 (0.5)</td><td align="char" rowspan="1" colspan="1">.08</td><td align="char" char="." rowspan="1" colspan="1">0.005</td><td align="char" rowspan="1" colspan="1">0.29</td><td align="char" char="." rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">6.9 (0.6)</td><td align="char" rowspan="1" colspan="1">0.1 (0.5)</td><td align="char" char="(" rowspan="1" colspan="1">0.1 (0.5)</td><td align="char" rowspan="1" colspan="1">.10</td><td align="char" char="." rowspan="1" colspan="1">0.45</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">HOMA&#x02010;IR</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">2.61 (1.91)</td><td align="char" rowspan="1" colspan="1">&#x02212;0.11 (1.02)</td><td align="char" char="(" rowspan="1" colspan="1">0.33 (1.74)</td><td align="char" rowspan="1" colspan="1">.28</td><td align="char" char="." rowspan="1" colspan="1">0.56</td><td align="char" rowspan="1" colspan="1">0.08</td><td align="char" char="." rowspan="1" colspan="1">.18</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">2.25 (1.78)</td><td align="char" rowspan="1" colspan="1">0.41 (1.43)</td><td align="char" char="(" rowspan="1" colspan="1">0.43 (1.18)</td><td align="char" rowspan="1" colspan="1">.12</td><td align="char" char="." rowspan="1" colspan="1">0.013</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">HOMA&#x02010;B%</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">48.2 (35.0)</td><td align="char" rowspan="1" colspan="1">&#x02212;1.6 (23.7)</td><td align="char" char="(" rowspan="1" colspan="1">0.5 (26.7)</td><td align="char" rowspan="1" colspan="1">.29</td><td align="char" char="." rowspan="1" colspan="1">0.80</td><td align="char" rowspan="1" colspan="1">0.34</td><td align="char" char="." rowspan="1" colspan="1">.68</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">56.0 (76.5)</td><td align="char" rowspan="1" colspan="1">3.5 (64.1)</td><td align="char" rowspan="1" colspan="1">&#x02212;5.7 (38.5)</td><td align="char" rowspan="1" colspan="1">.66</td><td align="char" char="." rowspan="1" colspan="1">0.71</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">Total cholesterol (mmol/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">4.09 (0.85)</td><td align="char" rowspan="1" colspan="1">0.03 (0.61)</td><td align="char" char="(" rowspan="1" colspan="1">0.02 (0.67)</td><td align="char" rowspan="1" colspan="1">.29</td><td align="char" char="." rowspan="1" colspan="1">0.80</td><td align="char" rowspan="1" colspan="1">0.64</td><td align="char" char="." rowspan="1" colspan="1">.99</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">4.15 (0.72)</td><td align="char" rowspan="1" colspan="1">0.03 (0.71)</td><td align="char" char="(" rowspan="1" colspan="1">0.01 (0.69)</td><td align="char" rowspan="1" colspan="1">.83</td><td align="char" char="." rowspan="1" colspan="1">0.75</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">LDL cholesterol (mmol/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">2.21 (0.68)</td><td align="char" rowspan="1" colspan="1">0.04 (0.44)</td><td align="char" char="(" rowspan="1" colspan="1">0.05 (0.51)</td><td align="char" rowspan="1" colspan="1">.53</td><td align="char" char="." rowspan="1" colspan="1">0.93</td><td align="char" rowspan="1" colspan="1">0.67</td><td align="char" char="." rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">2.30 (0.67)</td><td align="char" rowspan="1" colspan="1">0.00 (0.45)</td><td align="char" char="(" rowspan="1" colspan="1">0.02 (0.57)</td><td align="char" rowspan="1" colspan="1">1.00</td><td align="char" char="." rowspan="1" colspan="1">0.81</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">HDL cholesterol (mmol/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">1.13 (0.23)</td><td align="char" rowspan="1" colspan="1">0.04 (0.18)</td><td align="char" char="(" rowspan="1" colspan="1">0.06 (0.19)</td><td align="char" rowspan="1" colspan="1">.21</td><td align="char" char="." rowspan="1" colspan="1">0.051</td><td align="char" rowspan="1" colspan="1">0.64</td><td align="char" char="." rowspan="1" colspan="1">.98</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">1.26 (0.28)</td><td align="char" rowspan="1" colspan="1">0.04 (0.20)</td><td align="char" char="(" rowspan="1" colspan="1">0.05 (0.20)</td><td align="char" rowspan="1" colspan="1">.21</td><td align="char" char="." rowspan="1" colspan="1">0.14</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">Triglycerides (mmol/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">1.69 (1.59)</td><td align="char" rowspan="1" colspan="1">&#x02212;0.02 (0.85)</td><td align="char" rowspan="1" colspan="1">&#x02212;0.27 (1.50)</td><td align="char" rowspan="1" colspan="1">.52</td><td align="char" char="." rowspan="1" colspan="1">0.59</td><td align="char" rowspan="1" colspan="1">0.45</td><td align="char" char="." rowspan="1" colspan="1">.97</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">1.31 (0.71)</td><td align="char" rowspan="1" colspan="1">&#x02212;0.06 (0.66)</td><td align="char" rowspan="1" colspan="1">&#x02212;0.10 (0.58)</td><td align="char" rowspan="1" colspan="1">.57</td><td align="char" char="." rowspan="1" colspan="1">0.40</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">Adiponectin (&#x003bc;g/mL)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">8.3 (6.1)</td><td align="char" rowspan="1" colspan="1">&#x02212;0.7 (4.1)</td><td align="char" rowspan="1" colspan="1">&#x02212;0.5 (2.8)</td><td align="char" rowspan="1" colspan="1">.26</td><td align="char" char="." rowspan="1" colspan="1">0.37</td><td align="char" rowspan="1" colspan="1">0.52</td><td align="char" char="." rowspan="1" colspan="1">.99</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">9.3 (8.0)</td><td align="char" rowspan="1" colspan="1">&#x02212;1.8 (4.4)</td><td align="char" rowspan="1" colspan="1">&#x02212;1.2 (4.7)</td><td align="char" rowspan="1" colspan="1">.049</td><td align="char" char="." rowspan="1" colspan="1">0.20</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">hsCRP (mg/dL)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">0.13 (0.21)</td><td align="char" rowspan="1" colspan="1">0.04 (0.30)</td><td align="char" rowspan="1" colspan="1">&#x02212;0.02 (0.19)</td><td align="char" rowspan="1" colspan="1">.59</td><td align="char" char="." rowspan="1" colspan="1">0.99</td><td align="char" rowspan="1" colspan="1">0.49</td><td align="char" char="." rowspan="1" colspan="1">.90</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">0.15 (0.21)</td><td align="char" rowspan="1" colspan="1">&#x02212;0.02 (0.28)</td><td align="char" char="(" rowspan="1" colspan="1">0.03 (0.35)</td><td align="char" rowspan="1" colspan="1">.47</td><td align="char" char="." rowspan="1" colspan="1">0.97</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">PAI&#x02010;1 (&#x003bc;g/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">29.1 (18.5)</td><td align="char" rowspan="1" colspan="1">&#x02212;2.8 (10.1)</td><td align="char" rowspan="1" colspan="1">&#x02212;1.8 (12.8)</td><td align="char" rowspan="1" colspan="1">.10</td><td align="char" char="." rowspan="1" colspan="1">0.40</td><td align="char" rowspan="1" colspan="1">0.011</td><td align="char" char="." rowspan="1" colspan="1">.16</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">27.7 (19.4)</td><td align="char" rowspan="1" colspan="1">2.2 (16.1)</td><td align="char" char="(" rowspan="1" colspan="1">2.6 (27.1)</td><td align="char" rowspan="1" colspan="1">.11</td><td align="char" char="." rowspan="1" colspan="1">0.29</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">8&#x02010;isoprostane (ng/mL)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">10.7 (8.2)</td><td align="char" rowspan="1" colspan="1">1.5 (8.3)</td><td align="char" rowspan="1" colspan="1">&#x02212;1.0 (11.6)</td><td align="char" rowspan="1" colspan="1">.35</td><td align="char" char="." rowspan="1" colspan="1">0.67</td><td align="char" rowspan="1" colspan="1">0.37</td><td align="char" char="." rowspan="1" colspan="1">.33</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">8.1 (7.5)</td><td align="char" rowspan="1" colspan="1">3.8 (10.4)</td><td align="char" char="(" rowspan="1" colspan="1">2.4 (13.0)</td><td align="char" rowspan="1" colspan="1">.07</td><td align="char" char="." rowspan="1" colspan="1">0.33</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">Estimated GFR (mL/min)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">75.5 (21.2)</td><td align="char" rowspan="1" colspan="1">ND</td><td align="char" rowspan="1" colspan="1">&#x02212;2.2 (6.1)</td><td align="char" rowspan="1" colspan="1">ND</td><td align="char" char="." rowspan="1" colspan="1">.048</td><td align="char" rowspan="1" colspan="1">ND</td><td align="char" char="." rowspan="1" colspan="1">.89</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">78.0 (23.6)</td><td align="char" rowspan="1" colspan="1">ND</td><td align="char" char="(" rowspan="1" colspan="1">0.7 (11.6)</td><td align="char" rowspan="1" colspan="1">ND</td><td align="char" char="." rowspan="1" colspan="1">.42</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">Cystatin C (&#x003bc;g/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">0.79 (0.11)</td><td align="char" rowspan="1" colspan="1">&#x02212;0.01 (0.05)</td><td align="char" char="(" rowspan="1" colspan="1">0.01 (0.08)</td><td align="char" rowspan="1" colspan="1">.35</td><td align="char" char="." rowspan="1" colspan="1">.99</td><td align="char" rowspan="1" colspan="1">0.85</td><td align="char" char="." rowspan="1" colspan="1">.59</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">0.76 (0.16)</td><td align="char" rowspan="1" colspan="1">&#x02212;0.03 (0.11)</td><td align="char" char="(" rowspan="1" colspan="1">0.00 (0.11)</td><td align="char" rowspan="1" colspan="1">.52</td><td align="char" char="." rowspan="1" colspan="1">.67</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">baPWV, Right (cm/s)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">1594.7 (333.8)</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">55.0 (193.5)</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.09</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.05</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">1593.3 (318.1)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">&#x02212;40.6 (213.1)</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.27</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">baPWV, Left (cm/s)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">1606.9 (305.8)</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">29.0 (179.4)</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.39</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.046</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">1644.4 (330.3)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">&#x02212;63.7 (207.9)</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.08</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">ABI, Right</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">1.09 (0.13)</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">0.04 (0.09)</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.040</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.59</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">1.09 (0.09)</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">0.01 (0.08)</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.34</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">ABI, Left</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cilnidipine</td><td align="char" char="(" rowspan="1" colspan="1">1.09 (0.15)</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">0.03 (0.09)</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.06</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.49</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine</td><td align="char" char="(" rowspan="1" colspan="1">1.11 (0.08)</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">0.01 (0.09)</td><td align="char" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">.60</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="ijcp12987-note-0008"><label>a</label><p>Baseline vs 12&#x000a0;wk within group.</p></fn><fn id="ijcp12987-note-0009"><label>b</label><p>Baseline vs 24&#x000a0;wk within group.</p></fn><fn id="ijcp12987-note-0010"><label>c</label><p>12&#x000a0;wk between groups.</p></fn><fn id="ijcp12987-note-0011"><label>d</label><p>24&#x000a0;wk between groups.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="ijcp12987-sec-0015"><label>4</label><title>DISCUSSION</title><p>In the current randomized control study in 74 Korean patients with T2D and hypertension treated with RAS blocker, cilnidipine treatment significantly reduced urine albumin excretion after 12 and 24&#x000a0;weeks but, not with amlodipine treatment. Although cilnidipine treatment did not decrease urinary ACR in the total study population, the cilnidipine group showed a larger ACR reduction compared with the amlodipine group in patients with longer duration of diabetes more than 10&#x000a0;years.</p><p>There have been conflicting results regarding whether an L&#x02010;/N&#x02010;type CCB such as cilnidipine has additional renoprotective effects over an L&#x02010;type CCB such as amlodipine. In a study performed in patients with hypertension and kidney disease receiving RAS blocker, a 1&#x02010;year treatment with cilnidipine significantly decreased the urine protein excretion compared with amlodipine.<xref rid="ijcp12987-bib-0011" ref-type="ref">11</xref> In addition, urine albumin excretion decreased significantly in patients with T2D after changing from L&#x02010;type CCB to cilnidipine but not after changing from cilnidipine to an L&#x02010;type CCB.<xref rid="ijcp12987-bib-0016" ref-type="ref">16</xref> However, in this study, cilnidipine treatment did not show significant reduction in urinary ACR compared with amlodipine treatment, although cilnidipine decreased urinary ACR from baseline. We cannot clearly explain why the anti&#x02010;albuminuric effect of cilnidipine was not evident in our study, but we offer the following possibilities. First, contrary to previous studies,<xref rid="ijcp12987-bib-0011" ref-type="ref">11</xref>, <xref rid="ijcp12987-bib-0016" ref-type="ref">16</xref> blood pressure was already well controlled in our study and was less than 130/80&#x000a0;mm Hg at enrolment (mean of approximately 125/75&#x000a0;mm Hg in both groups).<xref rid="ijcp12987-bib-0017" ref-type="ref">17</xref>, <xref rid="ijcp12987-bib-0018" ref-type="ref">18</xref> Tight blood pressure control is essential for the prevention of progression of kidney disease<xref rid="ijcp12987-bib-0019" ref-type="ref">19</xref>; thus, the addition of another antihypertensive drug in our study may have had limited value in reducing ACR through blood pressure reduction. Systolic and diastolic blood pressure did not change after adding cilnidipine (Table&#x000a0;<xref rid="ijcp12987-tbl-0004" ref-type="table-wrap">4</xref>). Second, in our analysis, amlodipine treatment showed a greater reduction in blood pressure than cilnidipine treatment after 24&#x000a0;weeks, especially diastolic blood pressure (<italic>P</italic>=.03, Table&#x000a0;<xref rid="ijcp12987-tbl-0004" ref-type="table-wrap">4</xref>). Thus, a greater decrease in ACR could be anticipated with the addition of amlodipine than with cilnidipine. Third, we uniformly enrolled subjects treated with RAS blocker. However, only 28%&#x02010;62% of subjects with T2D in a previous study were treated with an RAS blocker.<xref rid="ijcp12987-bib-0016" ref-type="ref">16</xref> Thus, whether cilnidipine has an anti&#x02010;albuminuric effect in patients already receiving an RAS blocker remains uncertain. In accordance with our results, Ando et&#x000a0;al. reported that a 1&#x02010;year treatment with cilnidipine did not show a greater anti&#x02010;albuminuric effect than did amlodipine in patients with T2D and hypertension treated with an RAS blocker.<xref rid="ijcp12987-bib-0020" ref-type="ref">20</xref> The authors speculated that the sympatholytic action of cilnidipine is mild and thus, it can delay kidney injury only in patients without diabetes but, may be too weak to counteract the severe afferent arteriolar vasodilation caused by diabetes. Thus, cilnidipine could be more appropriate for patients with early&#x02010;stage diabetic nephropathy or hyperfiltrated kidney.<xref rid="ijcp12987-bib-0020" ref-type="ref">20</xref>
</p><p>Although cilnidipine treatment did not reduce urinary ACR in the total study population, adding cilnidipine to a RAS blocker had a greater effect on microalbuminuria than did amlodipine in patients with a long duration of T2D. We do not know why the anti&#x02010;albuminuric effect of cilnidipine was more evident compared with amlodipine in patients with a long duration of diabetes (&#x02265;10&#x000a0;years) compared with patients with a short duration of diabetes (&#x0003c;10&#x000a0;years). However, this result may be partly because of cilnidipine being a dual L&#x02010;/N&#x02010;type CCB; thus, the anti&#x02010;albuminuric effect of cilnidipine could have the greatest benefited in patients with sympathetic overactivity or autonomic dysfunction compared with amlodipine. Sympathetic nerve activity was reported to be enhanced in patients with diabetes,<xref rid="ijcp12987-bib-0021" ref-type="ref">21</xref> and the prevalence of diabetic cardiac autonomic neuropathy increases with duration of diabetes.<xref rid="ijcp12987-bib-0022" ref-type="ref">22</xref> Therefore, cilnidipine likely showed an anti&#x02010;albuminuric effect only in patients with a long duration of diabetes (&#x02265;10&#x000a0;years) who possibly have autonomic dysfunction.</p><p>In addition to its anti&#x02010;proteinuric effect, cilnidipine has been reported to have diverse favourable cardiometabolic effects.<xref rid="ijcp12987-bib-0023" ref-type="ref">23</xref>, <xref rid="ijcp12987-bib-0024" ref-type="ref">24</xref> Cilnidipine was reported to improve insulin sensitivity determined by the euglycemic clamp technique.<xref rid="ijcp12987-bib-0025" ref-type="ref">25</xref> In addition, cilnidipine was reported to improve insulin sensitivity and glucose tolerance, possibly by increasing high&#x02010;molecular weight adiponectin level in diet&#x02010;induced obese mice.<xref rid="ijcp12987-bib-0026" ref-type="ref">26</xref> However, in our analysis, fasting plasma glucose, HOMA&#x02010;IR, lipid profile, hsCRP, and adiponectin levels were similar between the two groups. The anti&#x02010;proteinuric effect of cilnidipine might be at least partly independent of its blood pressure&#x02010;lowering effect. Cilnidipine dilates both afferent and efferent arterioles and consequently reduces intraglomerular pressure, which is associated with its anti&#x02010;proteinuric properties.<xref rid="ijcp12987-bib-0010" ref-type="ref">10</xref> Cilnidipine reduced urine albumin excretion and 8&#x02010;hydroxy&#x02010;deoxyguanosine, a marker of oxidative stress, compared with amlodipine treatment.<xref rid="ijcp12987-bib-0027" ref-type="ref">27</xref> Therefore, the antioxidative properties of cilnidipine have been suggested to be associated with its anti&#x02010;proteinuric effect. However, our results did not show any differences in levels of 8&#x02010;isoprostane, a marker of oxidative stress; estimated GFR; or cystatin C, a maker of GFR,<xref rid="ijcp12987-bib-0028" ref-type="ref">28</xref> between the two groups. The lack of effect on oxidative stress and renal function may be partly associated with the inability of cilnidipine to reduce proteinuria.</p><p>This study has some limitations. The sample size was relatively small, and it was difficult to perform subgroup analyses. Although we recruited study participants based on two of three morning urine collections, urine was only collected once to determine the efficacy of treatment. We did not determine sympathetic activity of study participants; thus, it is unclear whether the anti&#x02010;albuminuric effect of cilnidipine differed from sympathetic activity in association with diabetes duration.</p><p>In conclusion, cilnidipine treatment did not decrease urine albumin excretion compared with amlodipine treatment in hypertensive patients with T2D and microalbuminuria who were treated with RAS blocker. However, the anti&#x02010;albuminuric effect of cilnidipine appeared to differ according to duration of diabetes and was greater than that of amlodipine in patients with a duration of diabetes longer than 10&#x000a0;years.</p></sec><sec id="ijcp12987-sec-0016"><title>ACKNOWLEDGEMENT</title><p>This study was financially supported by Boryung Pharmaceutical Co, Ltd, Seoul, Korea.</p></sec><sec id="ijcp12987-sec-0017"><title>DISCLOSURES</title><p>No potential conflicts of interest relevant to this article were reported.</p></sec><sec id="ijcp12987-sec-0018"><title>AUTHOR CONTRIBUTIONS</title><p>YCH analysed and interpreted the data, contributed to discussion, and wrote the manuscript. MKL designed the study, analysed and interpreted the data, and reviewed/edited the manuscript. KHY, BSC, KWL, HCJ, KWM, CHC and MKL collected the data, contributed to discussion and reviewed the manuscript.</p></sec></body><back><ack id="ijcp12987-sec-0019"><title>ORCID</title><p>Moon&#x02010;Kyu Lee&#x000a0;&#x000a0;<ext-link ext-link-type="uri" xlink:href="http://doi.org/0000-0002-8728-7184">http://doi.org/0000-0002-8728-7184</ext-link>
</p></ack><ref-list content-type="cited-references" id="ijcp12987-bibl-0001"><title>REFERENCES</title><ref id="ijcp12987-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0001">
<string-name>
<surname>de Zeeuw</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ramjit</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</string-name>, et&#x000a0;al. <article-title>Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL</article-title>. <source>Kidney Int</source>. <year>2006</year>;<volume>69</volume>:<fpage>1675</fpage>&#x02010;<lpage>1682</lpage>.<pub-id pub-id-type="pmid">16572114</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0002">
<string-name>
<surname>Gerstein</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Mann</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Yi</surname>
<given-names>Q</given-names>
</string-name>, et&#x000a0;al. <article-title>Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals</article-title>. <source>JAMA</source>. <year>2001</year>;<volume>286</volume>:<fpage>421</fpage>&#x02010;<lpage>426</lpage>.<pub-id pub-id-type="pmid">11466120</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0003">
<string-name>
<surname>de Zeeuw</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Remuzzi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Parving</surname>
<given-names>HH</given-names>
</string-name>, et&#x000a0;al. <article-title>Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>110</volume>:<fpage>921</fpage>&#x02010;<lpage>927</lpage>.<pub-id pub-id-type="pmid">15302780</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0004">
<string-name>
<surname>Vejakama</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Thakkinstian</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lertrattananon</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ingsathit</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ngarmukos</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Attia</surname>
<given-names>J</given-names>
</string-name>. <article-title>Reno&#x02010;protective effects of renin&#x02010;angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta&#x02010;analysis</article-title>. <source>Diabetologia</source>. <year>2012</year>;<volume>55</volume>:<fpage>566</fpage>&#x02010;<lpage>578</lpage>.<pub-id pub-id-type="pmid">22189484</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0005">
<string-name>
<surname>Bakris</surname>
<given-names>GL</given-names>
</string-name>. <article-title>A practical approach to achieving recommended blood pressure goals in diabetic patients</article-title>. <source>Arch Intern Med</source>. <year>2001</year>;<volume>161</volume>:<fpage>2661</fpage>&#x02010;<lpage>2667</lpage>.<pub-id pub-id-type="pmid">11732930</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0006">
<string-name>
<surname>Law</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Wald</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Jordan</surname>
<given-names>RE</given-names>
</string-name>. <article-title>Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials</article-title>. <source>BMJ</source>. <year>2003</year>;<volume>326</volume>:<fpage>1427</fpage>&#x02010;<lpage>1431</lpage>.<pub-id pub-id-type="pmid">12829555</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0007">
<string-name>
<surname>Wald</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Law</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Bestwick</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Wald</surname>
<given-names>NJ</given-names>
</string-name>. <article-title>Combination therapy versus monotherapy in reducing blood pressure: meta&#x02010;analysis on 11000 participants from 42 trials</article-title>. <source>Am J Med</source>. <year>2009</year>;<volume>122</volume>:<fpage>290</fpage>&#x02010;<lpage>300</lpage>.<pub-id pub-id-type="pmid">19272490</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0008">
<string-name>
<surname>Weber</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Bakris</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Jamerson</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>Cardiovascular events during differing hypertension therapies in patients with diabetes</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>56</volume>:<fpage>77</fpage>&#x02010;<lpage>85</lpage>.<pub-id pub-id-type="pmid">20620720</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0009">
<string-name>
<surname>Hayashi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wakino</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sugano</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ozawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Homma</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Saruta</surname>
<given-names>T</given-names>
</string-name>. <article-title>Ca<sup>2+</sup> channel subtypes and pharmacology in the kidney</article-title>. <source>Circ Res</source>. <year>2007</year>;<volume>100</volume>:<fpage>342</fpage>&#x02010;<lpage>353</lpage>.<pub-id pub-id-type="pmid">17307972</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0010">
<string-name>
<surname>Konnno</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kimura</surname>
<given-names>K</given-names>
</string-name>. <article-title>Vasodilatory effect of cilnidipine, an L&#x02010;type and N&#x02010;type calcium channel blocker, on rat kidney glomerular arteries</article-title>. <source>Int Heart J</source>. <year>2008</year>;<volume>49</volume>:<fpage>723</fpage>&#x02010;<lpage>732</lpage>.<pub-id pub-id-type="pmid">19075488</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0011">
<string-name>
<surname>Fujita</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ando</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nishimura</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin&#x02010;angiotensin inhibition in hypertensive patients with chronic renal disease</article-title>. <source>Kidney Int</source>. <year>2007</year>;<volume>72</volume>:<fpage>1543</fpage>&#x02010;<lpage>1549</lpage>.<pub-id pub-id-type="pmid">17943080</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0012">
<string-name>
<surname>Kojima</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Shida</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yokoyama</surname>
<given-names>H</given-names>
</string-name>. <article-title>Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases</article-title>. <source>Hypertens Res</source>. <year>2004</year>;<volume>27</volume>:<fpage>379</fpage>&#x02010;<lpage>385</lpage>.<pub-id pub-id-type="pmid">15253102</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0013">
<string-name>
<surname>Matthews</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Hosker</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Rudenski</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Naylor</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Treacher</surname>
<given-names>DF</given-names>
</string-name>, <string-name>
<surname>Turner</surname>
<given-names>RC</given-names>
</string-name>. <article-title>Homeostasis model assessment: insulin resistance and beta&#x02010;cell function from fasting plasma glucose and insulin concentrations in man</article-title>. <source>Diabetologia</source>. <year>1985</year>;<volume>28</volume>:<fpage>412</fpage>&#x02010;<lpage>419</lpage>.<pub-id pub-id-type="pmid">3899825</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0014">
<string-name>
<surname>Cockcroft</surname>
<given-names>DW</given-names>
</string-name>, <string-name>
<surname>Gault</surname>
<given-names>MH</given-names>
</string-name>. <article-title>Prediction of creatinine clearance from serum creatinine</article-title>. <source>Nephron</source>. <year>1976</year>;<volume>16</volume>:<fpage>31</fpage>&#x02010;<lpage>41</lpage>.<pub-id pub-id-type="pmid">1244564</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0015">
<string-name>
<surname>Bakker</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin&#x02010;to&#x02010;creatinine ratio over albumin concentration</article-title>. <source>Diabetes Care</source>. <year>1999</year>;<volume>22</volume>:<fpage>307</fpage>&#x02010;<lpage>313</lpage>.<pub-id pub-id-type="pmid">10333950</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0016">
<string-name>
<surname>Fukumoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ishimura</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Motoyama</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>Antialbuminuric advantage of cilnidipine compared with L&#x02010;type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2012</year>;<volume>97</volume>:<fpage>91</fpage>&#x02010;<lpage>98</lpage>.<pub-id pub-id-type="pmid">22336632</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0017">
<string-name>
<surname>Emdin</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Rahimi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Neal</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Callender</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Perkovic</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>A</given-names>
</string-name>. <article-title>Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis</article-title>. <source>JAMA</source>. <year>2015</year>;<volume>313</volume>:<fpage>603</fpage>&#x02010;<lpage>615</lpage>.<pub-id pub-id-type="pmid">25668264</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0018">
<collab collab-type="authors">ACCORD Study Group</collab>
, <string-name>
<surname>Cushman</surname>
<given-names>WC</given-names>
</string-name>, <string-name>
<surname>Evans</surname>
<given-names>GW</given-names>
</string-name>, et&#x000a0;al. <article-title>Effects of intensive blood&#x02010;pressure control in type 2 diabetes mellitus</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>362</volume>:<fpage>1575</fpage>&#x02010;<lpage>1585</lpage>.<pub-id pub-id-type="pmid">20228401</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0019">
<string-name>
<surname>James</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Oparil</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Carter</surname>
<given-names>BL</given-names>
</string-name>, et&#x000a0;al. <article-title>2014 evidence&#x02010;based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)</article-title>. <source>JAMA</source>. <year>2014</year>;<volume>311</volume>:<fpage>507</fpage>&#x02010;<lpage>520</lpage>.<pub-id pub-id-type="pmid">24352797</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0020">
<string-name>
<surname>Ando</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ueshima</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Comparison of the antialbuminuric effects of L&#x02010;/N&#x02010;type and L&#x02010;type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial</article-title>. <source>Int J Med Sci</source>. <year>2013</year>;<volume>10</volume>:<fpage>1209</fpage>&#x02010;<lpage>1216</lpage>.<pub-id pub-id-type="pmid">23935398</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0021">
<string-name>
<surname>Huggett</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Gilbey</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Stoker</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Mackintosh</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Mary</surname>
<given-names>DA</given-names>
</string-name>. <article-title>Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>108</volume>:<fpage>3097</fpage>&#x02010;<lpage>3101</lpage>.<pub-id pub-id-type="pmid">14676139</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0022">
<string-name>
<surname>Vinik</surname>
<given-names>AI</given-names>
</string-name>, <string-name>
<surname>Ziegler</surname>
<given-names>D</given-names>
</string-name>. <article-title>Diabetic cardiovascular autonomic neuropathy</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>115</volume>:<fpage>387</fpage>&#x02010;<lpage>397</lpage>.<pub-id pub-id-type="pmid">17242296</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0023">
<string-name>
<surname>Takahara</surname>
<given-names>A</given-names>
</string-name>. <article-title>Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release</article-title>. <source>Cardiovasc Ther</source>. <year>2009</year>;<volume>27</volume>:<fpage>124</fpage>&#x02010;<lpage>139</lpage>.<pub-id pub-id-type="pmid">19426250</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0024">
<string-name>
<surname>Kuwahara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kimura</surname>
<given-names>T</given-names>
</string-name>. <article-title>The organ&#x02010;protective effect of N&#x02010;type Ca(2+) channel blockade</article-title>. <source>Pharmacol Ther</source>. <year>2015</year>;<volume>151</volume>:<fpage>1</fpage>&#x02010;<lpage>7</lpage>.<pub-id pub-id-type="pmid">25659931</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0025">
<string-name>
<surname>Yagi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Goto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kurihara</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Katayama</surname>
<given-names>S</given-names>
</string-name>. <article-title>Effect of cilnidipine on insulin sensitivity in patients with essential hypertension</article-title>. <source>Hypertens Res</source>. <year>2003</year>;<volume>26</volume>:<fpage>383</fpage>&#x02010;<lpage>387</lpage>.<pub-id pub-id-type="pmid">12887129</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0026">
<string-name>
<surname>Ueno</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Masaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Gotoh</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Chiba</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kakuma</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yoshimatsu</surname>
<given-names>H</given-names>
</string-name>. <article-title>Cilnidipine regulates glucose metabolism and levels of high&#x02010;molecular adiponectin in diet&#x02010;induced obese mice</article-title>. <source>Hypertens Res</source>. <year>2013</year>;<volume>36</volume>:<fpage>196</fpage>&#x02010;<lpage>201</lpage>.<pub-id pub-id-type="pmid">23051658</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0027">
<string-name>
<surname>Soeki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kitani</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kusunose</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>Renoprotective and antioxidant effects of cilnidipine in hypertensive patients</article-title>. <source>Hypertens Res</source>. <year>2012</year>;<volume>35</volume>:<fpage>1058</fpage>&#x02010;<lpage>1062</lpage>.<pub-id pub-id-type="pmid">22763473</pub-id></mixed-citation></ref><ref id="ijcp12987-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="ijcp12987-cit-0028">
<string-name>
<surname>Filler</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>B&#x000f6;kenkamp</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hofmann</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Le Bricon</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Mart&#x000ed;nez&#x02010;Br&#x000fa;</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Grubb</surname>
<given-names>A</given-names>
</string-name>. <article-title>Cystatin C as a marker of GFR&#x02013;history, indications, and future research</article-title>. <source>Clin Biochem</source>. <year>2005</year>;<volume>38</volume>:<fpage>1</fpage>&#x02010;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15607309</pub-id></mixed-citation></ref></ref-list></back></article>